Insights

On September 6th,  Novo Nordisk announced it would release an authorized a generic versions of NovoLog® and NovoLog® Mix at a 50% discount compared to the brand version. The FDA states that “The term ‘authorized generic’ drug is most commonly used to describe an approved brand name drug that is marketed without the brand name […]

On October 13th, 2019, the Food and Drug Administration(FDA) announced some ranitidine products, including some medications commonly known as the brand-name drug Zantac, contain a nitrosamine impurity called N-nitrosodimethylamine (NDMA) at low levels. NDMA is classified as an agent that could cause cancer in humans. The FDA has been investigating NDMA and other nitrosamine impurities […]

OxyContin maker Purdue Pharma and the family that owns it has secured support from 23 states and thousands of local governments for a multibillion-dollar deal, to settle much of the opioid litigation it faces. The organization is offering $10 billion to $12 billion to resolve over 2,000 lawsuits alleging that the company played a role […]

Clients often ask about the future of rebates, which have been used by pharmacy benefits managers, health plans and plan sponsors to partially offset the cost of prescription drugs. In the past, rebates were viewed as a desirable financial component of the PBM pricing equation. Recently, however, rebates are viewed as a necessary evil. Rebates […]

Full Access to the PDF Report